Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth

Digestive and Liver Disease

Volumn 41, Issue 7, 2009, Pages 523-533

  Marzioni, M ^a   Invernizzi, P ^b,c   Candelaresi, C ^a   Maggioni, M ^b   Saccomanno, S ^a   Selmi, C ^c,d   Rychlicki, C ^a   Agostinelli, L ^a   Cassani, B ^b   Miozzo, M ^b   Pasini, S ^g   Fava, G ^a   Alpini, G ^e,f   Benedetti, A ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^f TEXAS A M COLLEGE OF MEDICINE   (United States)

^g SAN PAOLO HOSPITAL   (Italy)

Author keywords

Cholangiocarcinoma; Endogenous opioid peptides; Proliferation; Survival

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; DELTA OPIATE RECEPTOR; ELONGATION FACTOR 2 KINASE; MITOGEN ACTIVATED PROTEIN KINASE; OPIATE AGONIST; OPIATE PEPTIDE; OPIATE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C ALPHA;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BILE DUCT CARCINOMA; CANCER INCIDENCE; CARCINOGENESIS; CARCINOMA CELL; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DATA ANALYSIS; EARLY DIAGNOSIS; GROWTH REGULATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHOLANGIOCARCINOMA; HUMANS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 67349261559     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.09.011     Document Type: Article

References (53)

1. Ahrendt S.A., Nakeeb A., and Pitt H.A. Cholangiocarcinoma. Clin Liver Dis 5 (2001) 191-218
2. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2 (2002) 10
3. Lazaridis K.N., and Gores G.J. Cholangiocarcinoma. Gastroenterology 128 (2005) 1655-1667
4. Vauthey J.N., and Blumgart L.H. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 14 (1994) 109-114
5. Fava G., Marzioni M., Benedetti A., Glaser S., DeMorrow S., Francis H., et al. Molecular pathology of biliary tract cancers. Cancer Lett 250 (2007) 155-167
6. Alvaro D., Mancino M.G., Glaser S., Gaudio E., Marzioni M., Francis H., et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 132 (2007) 415-431
7. Marzioni M., Alpini G., Saccomanno S., de Minicis S., Glaser S., Francis H., et al. Endogenous opioids modulate the growth of the biliary tree in the course of cholestasis. Gastroenterology 130 (2006) 1831-1847
8. Zagon I.S., Hytrek S.D., and McLaughlin P.J. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Am J Physiol 271 (1996) R511-R518
9. Zagon I.S., Smith J.P., and McLaughlin P.J. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol 14 (1999) 577-584
10. Zagon I.S., Wu Y., and McLaughlin P.J. Opioid growth factor is present in human and mouse gastrointestinal tract and inhibits DNA synthesis. Am J Physiol 272 (1997) R1094-R1104
11. Panagiotou S., Hatzoglou A., Calvo F., Martin P.M., and Castanas E. Modulation of the estrogen-regulated proteins cathepsin D and pS2 by opioid agonists in hormone-sensitive breast cancer cell lines (MCF7 and T47D): evidence for an interaction between the two systems. J Cell Biochem 71 (1998) 416-428
12. Panagiotou S., Bakogeorgou E., Papakonstanti E., Hatzoglou A., Wallet F., Dussert C., et al. Opioid agonists modify breast cancer cell proliferation by blocking cells to the G2/M phase of the cycle: involvement of cytoskeletal elements. J Cell Biochem 73 (1999) 204-211
13. Bisignani G.J., McLaughlin P.J., Ordille S.D., Beltz M.S., Jarowenko M.V., and Zagon I.S. Human renal cell cancer proliferation in tissue culture is tonically inhibited by opioid growth factor. J Urol 162 (1999) 2186-2191
14. McLaughlin P.J., Levin R.J., and Zagon I.S. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by opioid growth factor. Int J Oncol 14 (1999) 991-998
15. Knuth A., Gabbert H., Dippold W., Klein O., Sachsse W., Bitter-Suermann D., et al. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol 1 (1985) 579-596
16. Kusaka Y., Muraoka A., Tokiwa T., and Sato J. Establishment and characterization of a human cholangiocellular carcinoma cell line. Hum Cell 1 (1988) 92-94
17. Saijyo S., Kudo T., Suzuki M., Katayose Y., Shinoda M., Muto T., et al. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med 177 (1995) 61-71
18. Fava G., Marucci L., Glaser S., Francis H., De Morrow S., Benedetti A., et al. gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res 65 (2005) 11437-11446
19. 2+-dependent protein kinase C-alpha. J Hepatol 34 (2001) 284-291
20. Bao L., Jin S.X., Zhang C., Wang L.H., Xu Z.Z., Zhang F.X., et al. Activation of delta opioid receptors induces receptor insertion and neuropeptide secretion. Neuron 37 (2003) 121-133
21. Zhang N., Rogers T.J., Caterina M., and Oppenheim J.J. Proinflammatory chemokines, such as C-C chemokine ligand 3, desensitize mu-opioid receptors on dorsal root ganglia neurons. J Immunol 173 (2004) 594-599
22. Sterpetti P., Marucci L., Candelaresi C., Toksoz D., Alpini G., Ugili L., et al. Cell proliferation and drug resistance in hepatocellular carcinoma are modulated by Rho GTPase signals. Am J Physiol Gastrointest Liver Physiol 290 (2006) G624-G632
23. Marzioni M., Glaser S., Francis H., Marucci L., Benedetti A., Alvaro D., et al. Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology 128 (2005) 121-137
24. Mancino A., Mancino M.G., Glaser S., Alpini G., Bolognese A., Izzo L., et al. Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig Liver Dis (2008)
25. Qiao L., Yacoub A., Studer E., Gupta S., Pei X.Y., Grant S., et al. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology 35 (2002) 779-789
26. Bucher B.T., Feng X., Jeyabalan G., Zhang B., Shao L., Guo Z., et al. Glycochenodeoxycholate (GCDC) inhibits cytokine induced iNOS expression in rat hepatocytes. J Surg Res 138 (2007) 15-21
27. Higuchi H., Yoon J.H., Grambihler A., Werneburg N., Bronk S.F., and Gores G.J. Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis. J Biol Chem 278 (2003) 454-461
28. Matsumoto K., Fujii H., Michalopoulos G., Fung J.J., and Demetris A.J. Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology 20 (1994) 376-382
29. Park J., Tadlock L., Gores G.J., and Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 30 (1999) 1128-1133
30. Endo K., Yoon B.I., Pairojkul C., Demetris A.J., and Sirica A.E. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 36 (2002) 439-450
31. Sirica A.E., Lai G.H., Endo K., Zhang Z., and Yoon B.I. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis 22 (2002) 303-313
32. Zhang Z., Lai G.H., and Sirica A.E. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 39 (2004) 1028-1037
33. Bergasa N.V., Liau S., Homel P., and Ghali V. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 22 (2002) 107-113
34. Bergasa N.V., Sabol S.L., Young III W.S., Kleiner D.E., and Jones E.A. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 268 (1995) G346-354
35. Bergasa N.V., Vergalla J., Swain M.G., and Jones E.A. Hepatic concentrations of proenkephalin-derived opioids are increased in a rat model of cholestasis. Liver 16 (1996) 298-302
36. Swain M.G., Rothman R.B., Xu H., Vergalla J., Bergasa N.V., and Jones E.A. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. Gastroenterology 103 (1992) 630-635
37. Nicoll J., Axiotis C.A., and Bergasa N.V. The delta opioid receptor 1 is expressed by proliferating bile ductules in rats with cholestasis: implications for the study of liver regeneration and malignant transformation of biliary epithelium. Med Hypotheses 65 (2005) 1099-1105
38. Baniahmad A. Nuclear hormone receptor co-repressors. J Steroid Biochem Mol Biol 93 (2005) 89-97
39. Robertson G.P. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev 24 (2005) 273-285
40. DeMorrow S., Glaser S., Francis H., Venter J., Vaculin B., Vaculin S., et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem 282 (2007) 13098-13113
41. Alvaro D., Barbaro B., Franchitto A., Onori P., Glaser S., Alpini G., et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol 169 (2006) 877-888
42. Hait W.N., and Lazo J.S. Calmodulin: a potential target for cancer chemotherapeutic agents. J Clin Oncol 4 (1986) 994-1012
43. Ito H., Wang J.Z., and Shimura K. Inhibition of lung metastasis by a calmodulin antagonist, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), in mice bearing Lewis lung carcinoma. Anticancer Res 11 (1991) 249-252
44. Ahn E.Y., Pan G., Oh J.H., Tytler E.M., and McDonald J.M. The combination of calmodulin antagonists and interferon-gamma induces apoptosis through caspase-dependent and -independent pathways in cholangiocarcinoma cells. Am J Pathol 163 (2003) 2053-2063
45. Chen Y., Xu J., Jhala N., Pawar P., Zhu Z.B., Ma L., et al. Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3′-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein. Am J Pathol 169 (2006) 1833-1842
46. Kobayashi S., Werneburg N.W., Bronk S.F., Kaufmann S.H., and Gores G.J. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 128 (2005) 2054-2065
47. Chiorean M.V., Guicciardi M.E., Yoon J.H., Bronk S.F., Kaufmanns S.H., and Gores G.J. Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. Liver Int 24 (2004) 687-695
48. Wu T., Leng J., Han C., and Demetris A.J. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 3 (2004) 299-307
49. Lin S.J., Chang C., Ng A.K., Wang S.H., Li J.J., and Hu C.P. Prevention of TGF-beta-induced apoptosis by interlukin-4 through Akt activation and p70S6K survival signaling pathways. Apoptosis 12 (2007) 1659-1670
50. Shen J., Jiang J., Wei Y., Zhou L., Liu D., Zhou J., et al. Two specific inhibitors of the phosphatidylinositol 3-kinase LY294002 and wortmannin up-regulate beta1,4-galactosyltransferase I and thus sensitize SMMC-7721 human hepatocarcinoma cells to cycloheximide-induced apoptosis. Mol Cell Biochem 304 (2007) 361-367
51. Thorgeirsson S.S., Teramoto T., and Factor V.M. Dysregulation of apoptosis in hepatocellular carcinoma. Semin Liver Dis 18 (1998) 115-122
52. New D.C., Wu K., Kwok A.W., and Wong Y.H. G protein-coupled receptor-induced Akt activity in cellular proliferation and apoptosis. FEBS J 274 (2007) 6025-6036
53. Marzioni M., Svegliati Baroni G., Alpini G., and Benedetti A. Endogenous opioid peptides and chronic liver disease: from bedside to bench. J Hepatol 46 (2007) 583-586